Interleukin Genetics (ILIU) 10-K/A 18 Apr 17 2016 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 13, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	INTERLEUKIN GENETICS INC
Entity Central Index Key	1,037,649
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,284,540
Trading Symbol	ILIU
Entity Common Stock, Shares Outstanding		229,471,392

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 2,657,214	$ 4,706,018
Accounts receivable from related party	74,535	39,989
Trade accounts receivable	31,354	45,973
Inventory	73,064	124,583
Prepaid expenses	434,983	778,970
Total prepaid expenses and other current assets	3,271,150	5,695,533
Fixed assets, net	511,192	643,900
Intangible assets, net	25,429	58,879
Other assets	28,001	93,208
Total assets	3,835,772	6,491,520
Current liabilities:
Accounts payable	505,630	408,374
Accrued expenses	238,087	497,688
Deferred revenue	2,502,966	3,238,541
Short term debt	2,304,545	1,333,333
Total current liabilities	5,551,228	5,477,936
Long term debt	1,130,094	3,474,984
Total liabilities	6,681,322	8,952,920
Stockholders’ deficit:
Convertible preferred stock, $0.001 par value - 6,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2016 and 2015, respectively	0	0
Common stock, $0.001 par value - 450,000,000 and 300,000,000 shares authorized; 229,381,059 and 172,887,221 shares issued and outstanding at December 31, 2016 and 2015, respectively	229,383	172,889
Additional paid-in capital	133,327,491	126,354,036
Accumulated deficit	(136,402,424)	(128,988,325)
Total stockholders’ deficit	(2,845,550)	(2,461,400)
Total liabilities and stockholders’ deficit	$ 3,835,772	$ 6,491,520

BALANCE SHEETS _Parenthetical_

BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	6,000,000	6,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	300,000,000
Common stock, shares issued	229,381,059	172,887,221
Common stock, shares outstanding	229,381,059	172,887,221

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Genetic testing	$ 1,032,317	$ 1,155,980
Other	1,481,139	284,930
Total revenue	2,513,456	1,440,910
Cost of revenue	1,601,958	1,414,113
Gross profit	911,498	26,797
Operating expenses:
Research and development	1,480,882	1,299,542
Selling, general and administrative	6,070,746	5,878,940
Amortization of intangibles	33,450	136,886
Total operating expenses	7,585,078	7,315,368
Loss from operations	(6,673,580)	(7,288,571)
Other income (expense):
Interest income	0	222
Interest expense	(740,519)	(609,664)
Total other expense	(740,519)	(609,442)
Loss before income taxes	(7,414,099)	(7,898,013)
Net loss	$ (7,414,099)	$ (7,898,013)
Basic and diluted net loss per common share (in dollars per share)	$ (0.04)	$ (0.05)
Weighted average common shares outstanding, basic and diluted (in shares)	197,089,020	172,813,224

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT - 12 months ended Dec. 31, 2016 - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (2,461,400)	$ 0	$ 172,889	$ 126,354,036	$ (128,988,325)
Balance (in shares) at Dec. 31, 2015		0	172,887,221
Net loss	(7,414,099)	$ 0	$ 0	0	(7,414,099)
Private placement of common stock, net of offering costs of $62,849	5,529,651	$ 0	$ 56,263	5,473,388	0
Private placement of common stock, net of offering costs of $62,849 (in shares)		0	56,262,571
Horizon warrant	503,667	$ 0	$ 0	503,667	0
Danforth warrant	8,885	0	0	8,885	0
Exercise of employee stock options	$ 0	$ 1	$ 0	67	0
Exercise of employee stock options (in shares)	1,316	1,316	66
Employee stock purchase plan	$ 15,991	$ 0	$ 230	15,761	0
Employee stock purchase plan (in shares)		0	229,951
Stock-based compensation expense	971,688	$ 0	$ 0	971,688	0
Balance at Dec. 31, 2016	$ (2,845,550)	$ 0	$ 229,383	$ 133,327,491	$ (136,402,424)
Balance (in shares) at Dec. 31, 2016		0	229,381,059

STATEMENTS OF STOCKHOLDERS_ DEF

STATEMENTS OF STOCKHOLDERS’ DEFICIT [Parenthetical]	12 Months Ended
	Dec. 31, 2016USD ($)
Payments of Stock Issuance Costs	$ 62,849
Common Stock [Member]
Payments of Stock Issuance Costs	$ 62,849

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (7,414,099)	$ (7,898,013)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation and amortization	251,021	349,254
Amortization of loan issuance costs and FV of warrants	171,127	108,224
Stock-based compensation expense	971,688	892,087
Changes in operating assets and liabilities:
Receivable from related party	(34,546)	(16,445)
Trade accounts receivable	14,619	(31,960)
Inventory	51,519	46,992
Prepaid expenses and other assets	343,987	(274,251)
Accounts payable	97,256	(105,553)
Accrued expenses	(259,601)	154,463
Deferred revenue	(735,575)	84,043
Net cash used in operating activities	(6,542,604)	(6,691,159)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions	(84,863)	(82,489)
Net cash used in investing activities	(84,863)	(82,489)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from private placement of common stock and warrants	5,592,500	0
Private placement offering costs	(62,849)	(8,095)
Payment of notes payable	(967,045)	0
Proceeds from employee stock purchase plan and employee option exercises	16,057	20,954
Net cash provided by financing activities	4,578,663	12,859
Net decrease in cash and equivalents	(2,048,804)	(6,760,789)
Cash, beginning of period	4,706,018	11,466,807
Cash, end of period	2,657,214	4,706,018
Supplemental disclosures of cash flow information:
Cash paid for interest	429,267	467,500
Supplemental disclosures of non-cash investing and financing activities:
Warrants issued in connection with long term debt amendment	$ 5,169,577	$ 0

Company Overview

Company Overview	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 1—Company Overview Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company’s principal operations and markets are located in the United States. Through 2016, the Company’s focus was on commercializing its ILUSTRA™ Inflammation Management Program (the “ILUSTRA Program”) and its Inherent Health ®

Operating Matters and Liquidity

Operating Matters and Liquidity	12 Months Ended
	Dec. 31, 2016
Going Concern [Abstract]
Operating Matters and Liquidity	Note 2—Operating Matters and Liquidity The Company has experienced net operating losses since its inception through December 31, 2016. The Company had net losses of $ 7.4 7.9 136.4 As of March 31, 2017, the Company has cash of approximately $ 791,000 1.1 3.6 5.5 As further discussed in Note 15 “Subsequent Events”, the Company issued and sold $ 1,000,000 These conditions, among others, considered in the aggregate raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Until such time, if ever, that the Company generates revenues sufficient to fund operations, the Company may fund its operations by issuing common stock, debt or other securities in one or more public or private offerings, as market conditions permit, or through the incurrence of debt from commercial lenders. Debt financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. There can be no assurance that additional funds will be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available to the Company on a timely basis, the Company may be required to delay, limit, reduce or cease activities or operations or enter into licenses or other arrangements with third parties on terms that may be unfavorable to the Company or sell, license or relinquish rights to develop or commercialize its products, technologies or intellectual property. However, no assurance can be given at this time as to whether the Company will be able to achieve these objectives. The ability of the Company to realize the carrying value of its fixed assets and intangible assets is especially dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets. The Company continues to take steps to reduce genetic test processing costs. Cost savings are primarily achieved through test process improvements. Management believes that the current laboratory space is adequate to process high volumes of genetic tests. On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $ 5.0 The loan was to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan would have been due and payable. 2,492,523 0.1003 On August 25, 2016, the Company and the Lender entered into the First Amendment of Venture Loan and Security Agreement and an Amended and Restated Secured Promissory Note (collectively referred to herein as the “2016 Debt Restructuring”), which was effective as of August 1, 2016, pursuant to which the principal payments due from August 2016 through December 2016 were reduced to 33 25,000 5,000 11.00 the final payment was increased from 4.5% of the loan, or $225,000, to 6.5% of the loan, or $325,000 11.27 5,169,577 0.0994 On July 29, 2016, the Company entered into a Securities Purchase Agreement (the “2016 Purchase Agreement”) with various accredited investors (the “2016 Investors”), pursuant to which the Company sold to the 2016 Investors in a private placement transaction (the “2016 Private Placement”) an aggregate of 56,262,571 0.0994 5.6 56,262,571 0.0994 .

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements. Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of December 31, 2016 and December 31, 2015, the Company had deferred genetic test revenue of $ 2.5 3.2 2.4 0.15 2.3 3.3 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the years ended December 31, 2016 and 2015 is $ 191,000 218,000 On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 225,000 302,000 Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2 Kit inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve was deemed necessary for the years ended December 31, 2016 and 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. Inventory is stored at a fulfillment provider. December 31, 2016 December 31, 2015 Raw materials $ 68,447 $ 112,372 Finished goods 4,617 12,211 Total inventory, net $ 73,064 $ 124,583 The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 36.4 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013, December 31, 2014 and September 30, 2016 the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. The Company has not performed an analysis to determine the extent of such limitations, if any. The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the year ended December 31, 2016. Research and development costs are expensed as incurred. The Company applies the provisions of FASB ASC 260, Earnings per Share As of December 31, 2016 2015 Options outstanding 31,363,319 21,657,776 Warrants outstanding 149,733,227 88,301,079 Total 181,096,546 109,958,855 Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. During the years ended December 31, 2016 and 2015, there were no items other than net loss included in the determination of comprehensive loss. The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model. The Company maintains its cash with a domestic financial institution that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2016, its concentration of credit risk related to cash was not significant. Cash is available on demand and is generally in excess of FDIC insurance limits. Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. The Company evaluates its long-lived assets, including intangible assets, for impairment whenever events or changes in circumstances indicate that carrying amounts of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. Any write-downs, based on fair value, are to be treated as permanent reductions in the carrying amount of the assets. For the year ended December 31, 2015, the Company recorded a write down of $ 66,000 As of December 31, 2016 and 2015, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. Revenue from the Company’s genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test or the requesting physician. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. The Company is not electing to adopt early and is evaluating the impact of ASU 2014-09 on the Company’s financial disclosures. FASB ASU 2016-02 - Leases (Topic 842). In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. FASB ASU No. 2016-09, - Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 4—Related Party Transactions Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations. On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 225,000 302,000 In 2012 and 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $ 3.3 1.5 1.8 519,000 250,000 On September 21, 2012, the Company entered into a License Agreement (the “License Agreement”) with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least 60 199,000 191,000 In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the years ended December 31, 2016 and 2015 under the PSA. For years ended December 31, 2016 and 2015, approximately 24 45 4 13 On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company. terminated on February 25, 2016. A revised agreement with substantially similar terms was executed in April 2016.

Debt Instruments

Debt Instruments	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Instruments	Note 5—Debt Instruments Venture Loan and Security Agreement On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $ 5.0 The loan bore interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeded 0.50%, the interest rate would have been adjusted by an amount equal to the difference between such rates at the end of that particular month. The loan was to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest (the “Payment Terms”). In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan would have been due and payable. 2,492,523 0.1003 On August 25, 2016, the Company and the Lender entered into the First Amendment of Venture Loan and Security Agreement and an Amended and Restated Secured Promissory Note (collectively referred to herein as the “2016 Debt Restructuring”), which was effective as of August 1, 2016, pursuant to which the principal payments due from August 2016 through December 2016 was reduced to 33 25,000 5,000 11.00 one month LIBOR Rate exceeds 0.50% 11.27 5,169,577 0.0994 The Company recorded a discount on the loan comprised of (i) $ 89,000 261,000 30,000 504,000 579,000 325,000 429,000 456,000 294,000 153,000

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2016
Assets [Abstract]
Fixed Assets	Note 6—Fixed Assets Useful Life 2016 2015 Computer software, computer equipment and office equipment 3 years $ 516,511 $ 516,511 Laboratory equipment 5 years 1,896,417 1,887,454 Furniture and fixtures 5 years 40,349 40,349 Leasehold improvements 5 years 309,618 309,618 Website development 3 years 374,453 298,553 3,137,348 3,052,485 Less — Accumulated depreciation and amortization (2,626,156) (2,408,585) Total $ 511,192 $ 643,900 Depreciation and amortization expense was $ 218,000 212,000

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2016
Intangible Assets [Abstract]
Intangible Assets	Note 7—Intangible Assets 2016 2015 Patent costs $ 1,154,523 $ 1,154,523 Less — Accumulated amortization (1,129,094) (1,029,497) Less — Write off related to patents no longer in use — (66,147) Total $ 25,429 $ 58,879 Patent amortization expense was $ 33,000 137,000 10 Year ended December 31, 2017 19,117 2018 6,312 $ 25,429

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Note 8—Accrued Expenses Accrued expenses at December 31, 2016 and 2015 consisted of the following: 2016 2015 Payroll and vacation $ 81,928 $ 412,674 Other 156,159 85,014 Total accrued expenses $ 238,087 $ 497,688

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and contingencies	Note 9—Commitments and Contingencies Off-Balance Sheet Arrangements The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows. Employment Agreements On May 19, 2016, the Company entered into an employment agreement with Stephan Toutain for the position of Chief Commercial Officer beginning on August 15, 2016 (the “Start Date”). The agreement provides for a minimum annual base salary of $ 315,000 30 3,738,933 1 25 2.083 Bonus Plan On February 26, 2014, the Compensation Committee approved an Employee Bonus Plan (the “Employee Bonus Plan”) that replaces the Bonus Plan approved on December 21, 2012. Under the Employee Bonus Plan, bonuses may be awarded upon the achievement of corporate goals, however, the Compensation Committee has absolute discretion as to whether bonuses will be awarded and the size of any bonus, notwithstanding whether any such corporate goals are met. Bonus accruals totaling $ 166,000 Operating Leases The Company leases its office and laboratory space under a non-cancelable operating lease which is scheduled to expire on March 31, 2017 2.06 2.06 2.88 Year Ended Office Total December 31, Office Lease Copier Lease Net Lease Equipment Payments, Net 2017 335,279 6,624 341,903 2,226 344,129 2018 345,020 1,104 346,124 1,484 347,608 2019 86,864 — 86,864 — 86,864 $ 767,163 7,728 $ 774,891 $ 3,710 $ 778,601 Rent expense was $ 347,000 352,000

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2016
Capital Stock [Abstract]
Capital Stock	Note 10—Capital Stock Authorized Preferred and Common Stock As of December 31, 2016, the Company has 6,000,000 0.001 450,000,000 0.001 229,381,059 Reserved for Strike issuance Price Expiry Shares reserved under outstanding stock options and options available for grant 52,092,463 Rights associated with Employee Stock Purchase Plan 70,122 Warrants to purchase common stock associated with the 2016 Debt Restructuring 5,169,577 $ 0.0994 Aug 1, 2026 Warrants to purchase common stock associated with July 2016 private placement 56,262,571 $ 0.0994 Jul 29, 2023 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 Dec 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 Dec 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 Sep 8, 2024 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 Aug 9, 2020 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in June 2012 437,158 $ 0.2745 Jun 29, 2017 Total common shares reserved for issuance at December 31, 2016 201,895,812 Total common shares issued and outstanding at December 31, 2016 229,381,059 Total common shares outstanding and reserved for issuance at December 31, 2016 431,276,871 On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 63 37 150,000,000 300,000,000 For its services in this transaction, the placement agent received cash compensation in the amount of approximately $ 780,000 2,295,082 0.2745 In connection with the May 2013 Private Placement, all preferred stockholders converted their shares of Preferred Stock to common stock resulting in the issuance of 39,089,161 14,316,255 2,521,222 In September 2014, the Company issued warrants to financial consultant, Danforth Advisors, to purchase up to 100,000 0.25 24,000 9,000 12,000 On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 For services related to this transaction, the placement agent, its legal counsel and the Company’s legal counsel received an aggregate of $ 218,000 89,731 The 2014 Warrants and the 2014 Placement Agent Warrants were recorded as equity at fair value on the date of issuance. On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $ 5.2 9,000 On July 29, 2016, the Company entered into the 2016 Purchase Agreement with the 2016 Investors, pursuant to which the Company sold to the 2016 Investors in the 2016 Private Placement an aggregate of 56,262,571 0.0994 5.6 56,262,571 0.0994 For services related to this transaction, the Company’s legal counsel received $ 63,000 6.5 July 29, 2016 Risk-free interest rate 1.52 % Expected life 7 years Expected volatility 147.03 % Dividend yield 0 % Registration Rights Agreements In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015. In connection with the July 2016 Private Placement, on July 29, 2106, the Company also entered into a Registration Rights Agreement with the 2016 Investors, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of July 29, 2016 to cover the resale of the shares of common stock sold to the 2016 Investors and the shares of common stock underlying the 2016 Warrants. The Company filed the registration statement on September 12, 2016, and it was declared effective on September 27, 2016. Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with the Lender under which the Company has borrowed $ 5.0 2,492,523 0.1003 261,000 On August 25, 2016, the Company and The Lender agreed to the 2016 Debt Restructuring, which was effective as of August 1, 2016, pursuant to which the principal payments due from August 2016 through December 2016 were reduced to 33 5,169,577 0.0994 The 2014 Lender Warrants and 2016 Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Lender Warrants and 2016 Lender Warrants was calculated using the Black-Scholes model. August 1, 2016 Risk-free interest rate 1.78 % Expected life 10 years Expected volatility 138.81 % Dividend yield 0 % The fair value of the 2016 Lender Warrants at issuance was $ 504,000 429,000 456,000 294,000 153,000 579,000 2017 2,304,545 2018 1,920,455 $ 4,225,000

Stock-Based Compensation Arrang

Stock-Based Compensation Arrangements	12 Months Ended
	Dec. 31, 2016
Stock-Based Compensation Arrangements [Abstract]
Stock-Based Compensation Arrangements	Note 11—Stock-Based Compensation Arrangements On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 2,435,500 30,000,000 10,622,392 20,729,144 Stock Option Grants Per his employment agreement, Mark Carbeau was entitled to receive a grant of options to purchase shares of the Company’s common stock equal to 5 5,626,257 5,000,000 5,000,000 0.17544 These options will vest as to 25% of the shares on July 29, 2017 and as to an additional 2.083% of the shares on the last day of each successive month thereafter Per his employment agreement, Stephan Toutain was entitled to receive a grant of options to purchase shares of the Company’s common stock equal to 1 3,738,933 0.17544 These options will vest as to 25% of the shares on August 15, 2017, and as to an additional 2.083% of the shares monthly thereafter. It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance. 2016 2015 Risk-free interest rate 1.24 % 1.54 % Expected life 5.73 years 5.73 years Expected volatility 146.3 % 138.8 % Dividend yield 0 % 0 % Using these assumptions, the weighted average grant date fair value of options granted in 2016 and 2015 was $ 0.15 0.16 Restricted Stock Awards Holders of restricted stock awards participate fully in the rewards of stock ownership of the Company, including voting and dividend rights. Recipients of restricted stock awards are generally not required to pay any consideration to the Company for these restricted stock awards. The Company measures the fair value of the shares based on the last reported price at which the Company’s common stock traded on the date of the grant and compensation cost is recognized over the remaining service period. During each of the years ended December 31, 2016 and 2015, the Company granted no restricted stock awards. Employee Stock Purchase Plan Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85 229,951 203,879 0.08 0.10 0.09 0.12 2,921 4,053 2016 2015 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Granted 10,622,392 0.16 18,193,027 0.17 Stock options exercised (1,316) .05 –– 0.00 Restricted stock exercised –– 0.00 –– 0.00 Forfeited/Expired (915,533) 0.33 (1,059,151) 0.17 Outstanding, end of period 31,363,319 $ 0.19 21,657,776 $ 0.21 Exercisable, end of period 10,860,050 $ 0.23 3,665,124 $ 0.32 Stock Options/Restricted Stock Stock Options/Restricted Stock Outstanding Exercisable Weighted Avg. remaining Weighted Avg. Weighted Avg. contractual life Exercise Exercise Range of Exercise Price: Shares (years) Price Shares Price $0.01–$1.00 31,318,319 8.55 $ 0.19 10,815,050 $ 0.23 $1.01–$2.00 45,000 1.25 1.40 45,000 1.40 $2.01–$3.00 –– –– –– –– –– $3.01–$4.00 –– –– –– –– –– $4.01–$5.00 –– –– –– –– –– 31,363,319 8.54 $ 0.19 10,860,050 $ 0.23 Aggregate intrinsic value $ 69,547 $ 0 The aggregate intrinsic value in the preceding table is based on the last reported price at which the Company’s common stock traded on December 31, 2016, of $ 0.11 2016 2015 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Non-vested options, beginning of year 17,992,652 $ 0.18 2,878,739 $ 0.37 Granted 10,622,392 0.16 18,193,027 0.17 Vested (8,035,609) 0.15 (2,038,435) 0.33 Forfeited (76,166) 0.25 (1,040,679) 0.17 Non-vested options, end of year 20,503,269 $ 0.17 17,992,652 $ 0.18 Year Ended December 31, 2016 2015 Stock option grants beginning of period $ 846,347 $ 730,102 Stock-based arrangements during the period: Stock option grants 122,420 157,932 Restricted stock issued: Employee stock purchase plan 2,921 4,053 Director agreements –– –– $ 971,688 $ 892,087 As of December 31, 2016 and 2015, there was approximately $ 2,705,027 2,248,591 2.8 3.11

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Note 12—Employee Benefit Plan The Company sponsors a profit sharing plan covering substantially all of its employees. The profit sharing plan allows for pre-tax employee contributions. The Company may, at the discretion of the Board of Directors, match a portion of the participant contributions. The Company currently contributes 25 1,500 13,520 2,239

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 13—Income Taxes For the years ended December 31, 2016 and 2015, the Company recorded no tax provision or benefit. While the Company has incurred losses from operations it has not recorded an income tax benefit for 2016 or 2015 as it has recorded a valuation allowance against net operating losses and other net deferred tax assets due to uncertainties related to the ability of these tax assets to be realized. Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted federal and state tax rates in effect for the year in which the differences are expected to reverse. 2016 2015 Deferred tax asset: Tax effect of: Net operating loss carryforwards $ 31,398,000 $ 29,122,000 Accrued expenses 19,000 87,000 Amortization of definite lived intangible assets –– 10,000 Non-qualified stock option compensation 598,000 315,000 Depreciation 68,000 72,000 Deferred revenue 943,000 880,000 Other 1,000 139,000 Patents –– (23,000) Deferred gain on installment sale (1,000) –– State net operating loss carryforwards, net of federal tax benefit 929,000 579,000 Research tax credit carryforwards 2,433,000 2,274,000 Total deferred tax assets 36,388,000 33,455,000 Valuation allowance (36,388,000) (33,455,000) Net deferred tax assets $ - $ - As of December 31, 2016, the Company had gross net operating loss (NOL) and research tax credit carryforwards of approximately $ 94.9 1.7 2036 94.9 2.5 As of December 31, 2016, the Company had gross NOL and research tax credit carryforwards of approximately $ 17.6 1.1 The Company’s ability to use its NOL and tax credit carryforwards to reduce future taxes is subject to the restrictions provided by Section 382 of the Internal Revenue Code of 1986. These restrictions provide for limitations on the Company’s utilization of its NOL and tax credit carryforwards following a greater than 50 The Company is subject to taxation in the United States and the Commonwealth of Massachusetts. As of December 31, 2016, tax years for 2013, 2014 and 2015 are subject to examination by the tax authorities. Since the Company is in a loss carry-forward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carry-forward is utilized. However, carryforward attributes from prior years may still be adjusted upon examination by tax authorities if they are used in an open period. 2016 2015 Tax at statutory rate (34.0) % (34.0) % State taxes, net of federal benefit 0.0 0.0 Research and development credit (0.69) (1.3) Share based payment expense 0.0 1.6 Other 0.42 0.7 Removal of deferred tax asset on federal net operating losses 0.00 0.0 Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits (5.3) (4.9) Change in valuation allowance 39.6 37.9 Effective tax rate 0.0 % 0.0 %

Risks and Uncertainties

Risks and Uncertainties	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Risks and Uncertainties	Note 14—Risks and Uncertainties The Company develops genetic risk assessment tests and performs research for its own benefit. As of December 31, 2016, the Company has introduced five genetic risk assessment tests commercially. Commercial success of the Company’s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners. Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated. During the years ended December 31, 2016 and 2015, approximately 24 45 4 13

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 15—Subsequent Events In January 2017, Mark Carbeau was granted an option to purchase 1,278,653 0.1237 In January 2017, Kenneth Kornman was granted an option to purchase 3,625,746 0.1237 In January 2017, Stephan Toutain was granted an option to purchase 365,093 0.1237 On April 17, 2017, the Company sold $ 500,000 1,000,000 Also on April 17, 2017, the Company entered into a series of agreements, including the Second Amendment of Venture Loan and Security Agreement and a warrant to purchase common stock, to restructure its existing debt under the Loan Agreement with the Lender, which resulted in the deferral of the principal amount due to the Lender on April 1, May 1, and June 1, 2017, and the potential deferral of the principal amount due to the Lender on July 1, August 1 and September 1, 2017, such potential deferral of principal is dependent upon whether, as of June 15, 2017, the Company provides evidence reasonably satisfactory to the Lender that the Company is actively negotiating a clinical services or similar agreement, the terms of which are satisfactory to the Lender, which the Company believes, in good faith, it will enter into no later than September 1, 2017. In exchange for agreeing to defer principal payments, the Lender was granted a warrant to purchase common stock. The number of shares of common stock issuable upon exercise of the warrant is determined by dividing the amount of principal payments deferred by the exercise price of the warrant, which could result in the warrant being exercisable for between approximately 5,519,604 11,039,209 0.10438 10 On March 31, 2017, the Company announced that the Board of Directors had approved a work force restructuring, which became effective and was completed on March 30, 2017, to better utilize the Company’s resources, to align the Company’s organization to support its emerging cardiovascular testing program, for which it is seeking strategic interest, and to streamline its commercial strategy for its ILUSTRA Inflammation Management Program. As a consequence of the restructuring, the Company reduced its workforce in its commercial organization and administrative functions by eight persons. We continue to support the ILUSTRA Program deployments with customers and will advance new customer relationships that expand the evidence base of this program’s effectiveness.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
Revenue Recognition	Revenue Recognition Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of December 31, 2016 and December 31, 2015, the Company had deferred genetic test revenue of $ 2.5 3.2 2.4 0.15 2.3 3.3 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the years ended December 31, 2016 and 2015 is $ 191,000 218,000
Sales Commissions	Sales Commission On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 225,000 302,000
Accounts Receivable	Accounts Receivable Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2
Inventory	Inventory Kit inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve was deemed necessary for the years ended December 31, 2016 and 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. Inventory is stored at a fulfillment provider. December 31, 2016 December 31, 2015 Raw materials $ 68,447 $ 112,372 Finished goods 4,617 12,211 Total inventory, net $ 73,064 $ 124,583
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 36.4 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013, December 31, 2014 and September 30, 2016 the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. The Company has not performed an analysis to determine the extent of such limitations, if any. The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the year ended December 31, 2016.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company applies the provisions of FASB ASC 260, Earnings per Share As of December 31, 2016 2015 Options outstanding 31,363,319 21,657,776 Warrants outstanding 149,733,227 88,301,079 Total 181,096,546 109,958,855
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. During the years ended December 31, 2016 and 2015, there were no items other than net loss included in the determination of comprehensive loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
Cash and Cash Equivalents	Cash The Company maintains its cash with a domestic financial institution that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2016, its concentration of credit risk related to cash was not significant. Cash is available on demand and is generally in excess of FDIC insurance limits.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, including intangible assets, for impairment whenever events or changes in circumstances indicate that carrying amounts of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. Any write-downs, based on fair value, are to be treated as permanent reductions in the carrying amount of the assets. For the year ended December 31, 2015, the Company recorded a write down of $ 66,000
Segment Reporting	Segment Reporting As of December 31, 2016 and 2015, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
Recent Accounting Pronouncements	Recent Accounting Pronouncements FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. Revenue from the Company’s genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test or the requesting physician. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. The Company is not electing to adopt early and is evaluating the impact of ASU 2014-09 on the Company’s financial disclosures. FASB ASU 2016-02 - Leases (Topic 842). In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements. FASB ASU No. 2016-09, - Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Abstract]
Inventory	Inventory consisted of the following at December 31, 2016 and 2015: December 31, 2016 December 31, 2015 Raw materials $ 68,447 $ 112,372 Finished goods 4,617 12,211 Total inventory, net $ 73,064 $ 124,583
Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share	Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows: As of December 31, 2016 2015 Options outstanding 31,363,319 21,657,776 Warrants outstanding 149,733,227 88,301,079 Total 181,096,546 109,958,855

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Assets [Abstract]
Schedule of useful lives and balances of fixed assets	The useful lives and balances of fixed assets at December 31, 2016 and 2015 consisted of the following: Useful Life 2016 2015 Computer software, computer equipment and office equipment 3 years $ 516,511 $ 516,511 Laboratory equipment 5 years 1,896,417 1,887,454 Furniture and fixtures 5 years 40,349 40,349 Leasehold improvements 5 years 309,618 309,618 Website development 3 years 374,453 298,553 3,137,348 3,052,485 Less — Accumulated depreciation and amortization (2,626,156) (2,408,585) Total $ 511,192 $ 643,900

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Intangible Assets [Abstract]
Summary of Intangible Assets	Intangible assets at December 31, 2016 and 2015 consisted of the following: 2016 2015 Patent costs $ 1,154,523 $ 1,154,523 Less — Accumulated amortization (1,129,094) (1,029,497) Less — Write off related to patents no longer in use — (66,147) Total $ 25,429 $ 58,879
Patent Costs Amortized on a Straight-Line Basis	Patent costs which are being amortized on a straight-line basis over a 10 Year ended December 31, 2017 19,117 2018 6,312 $ 25,429

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	Accrued expenses at December 31, 2016 and 2015 consisted of the following: 2016 2015 Payroll and vacation $ 81,928 $ 412,674 Other 156,159 85,014 Total accrued expenses $ 238,087 $ 497,688

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease commitments under non-cancelable lease agreements with initial or remaining terms of one year or more at December 31, 2015, are as follows: Year Ended Office Total December 31, Office Lease Copier Lease Net Lease Equipment Payments, Net 2017 335,279 6,624 341,903 2,226 344,129 2018 345,020 1,104 346,124 1,484 347,608 2019 86,864 — 86,864 — 86,864 $ 767,163 7,728 $ 774,891 $ 3,710 $ 778,601

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Authorized, Issued and Reserved shares of common stock	As of December 31, 2016 the Company has 229,381,059 Reserved for Strike issuance Price Expiry Shares reserved under outstanding stock options and options available for grant 52,092,463 Rights associated with Employee Stock Purchase Plan 70,122 Warrants to purchase common stock associated with the 2016 Debt Restructuring 5,169,577 $ 0.0994 Aug 1, 2026 Warrants to purchase common stock associated with July 2016 private placement 56,262,571 $ 0.0994 Jul 29, 2023 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 Dec 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 Dec 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 Sep 8, 2024 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 Aug 9, 2020 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in June 2012 437,158 $ 0.2745 Jun 29, 2017 Total common shares reserved for issuance at December 31, 2016 201,895,812 Total common shares issued and outstanding at December 31, 2016 229,381,059 Total common shares outstanding and reserved for issuance at December 31, 2016 431,276,871
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	The fair value of the 2016 Warrants at issuance was $ 6.5 July 29, 2016 Risk-free interest rate 1.52 % Expected life 7 years Expected volatility 147.03 % Dividend yield 0 %
Principal payments due under the terms of Loan Agreement	Principal payments due under the terms of the Loan Agreement and the 2016 Debt Restructuring are as follows: 2017 2,304,545 2018 1,920,455 $ 4,225,000
Lender Warrants [Member]
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	Fair value of the 2016 Lender Warrants was calculated using the following inputs in a Black-Scholes model: August 1, 2016 Risk-free interest rate 1.78 % Expected life 10 years Expected volatility 138.81 % Dividend yield 0 %

Stock-Based Compensation Arra30

Stock-Based Compensation Arrangements (Tables)	12 Months Ended
	Dec. 31, 2016
Stock-Based Compensation Arrangements [Abstract]
Stock-based compensation expense for stock option awards	For purposes of determining the stock-based compensation expense for stock option awards in 2016 and 2015, the Black-Scholes option-pricing model was used with the following weighted-average assumptions: 2016 2015 Risk-free interest rate 1.24 % 1.54 % Expected life 5.73 years 5.73 years Expected volatility 146.3 % 138.8 % Dividend yield 0 % 0 %
Common Stock Weighted Average Purchase Price	The following table details stock option and restricted stock activity for the years ended December 31, 2016 and 2015. 2016 2015 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Granted 10,622,392 0.16 18,193,027 0.17 Stock options exercised (1,316) .05 –– 0.00 Restricted stock exercised –– 0.00 –– 0.00 Forfeited/Expired (915,533) 0.33 (1,059,151) 0.17 Outstanding, end of period 31,363,319 $ 0.19 21,657,776 $ 0.21 Exercisable, end of period 10,860,050 $ 0.23 3,665,124 $ 0.32
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	The following table details further information regarding stock options and restricted stock outstanding and exercisable at December 31, 2016: Stock Options/Restricted Stock Stock Options/Restricted Stock Outstanding Exercisable Weighted Avg. remaining Weighted Avg. Weighted Avg. contractual life Exercise Exercise Range of Exercise Price: Shares (years) Price Shares Price $0.01–$1.00 31,318,319 8.55 $ 0.19 10,815,050 $ 0.23 $1.01–$2.00 45,000 1.25 1.40 45,000 1.40 $2.01–$3.00 –– –– –– –– –– $3.01–$4.00 –– –– –– –– –– $4.01–$5.00 –– –– –– –– –– 31,363,319 8.54 $ 0.19 10,860,050 $ 0.23 Aggregate intrinsic value $ 69,547 $ 0
Schedule Of Non-Vested Options	The following table summarizes the status of the Company’s non-vested options for the years ended December 31, 2016 and 2015: 2016 2015 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Non-vested options, beginning of year 17,992,652 $ 0.18 2,878,739 $ 0.37 Granted 10,622,392 0.16 18,193,027 0.17 Vested (8,035,609) 0.15 (2,038,435) 0.33 Forfeited (76,166) 0.25 (1,040,679) 0.17 Non-vested options, end of year 20,503,269 $ 0.17 17,992,652 $ 0.18
Total Compensation Cost Recorded for Stock-Based Compensation	Total cost for stock-based compensation arrangements is as follows: Year Ended December 31, 2016 2015 Stock option grants beginning of period $ 846,347 $ 730,102 Stock-based arrangements during the period: Stock option grants 122,420 157,932 Restricted stock issued: Employee stock purchase plan 2,921 4,053 Director agreements –– –– $ 971,688 $ 892,087

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2016 and 2015, the expected income tax effect of the Company’s deferred tax assets (liabilities) consisted of the following: 2016 2015 Deferred tax asset: Tax effect of: Net operating loss carryforwards $ 31,398,000 $ 29,122,000 Accrued expenses 19,000 87,000 Amortization of definite lived intangible assets –– 10,000 Non-qualified stock option compensation 598,000 315,000 Depreciation 68,000 72,000 Deferred revenue 943,000 880,000 Other 1,000 139,000 Patents –– (23,000) Deferred gain on installment sale (1,000) –– State net operating loss carryforwards, net of federal tax benefit 929,000 579,000 Research tax credit carryforwards 2,433,000 2,274,000 Total deferred tax assets 36,388,000 33,455,000 Valuation allowance (36,388,000) (33,455,000) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	The benefit for income taxes differs from the federal statutory rate due to the following: 2016 2015 Tax at statutory rate (34.0) % (34.0) % State taxes, net of federal benefit 0.0 0.0 Research and development credit (0.69) (1.3) Share based payment expense 0.0 1.6 Other 0.42 0.7 Removal of deferred tax asset on federal net operating losses 0.00 0.0 Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits (5.3) (4.9) Change in valuation allowance 39.6 37.9 Effective tax rate 0.0 % 0.0 %

Operating Matters and Liquidi32

Operating Matters and Liquidity - Additional Information (Detail) - USD ($)	1 Months Ended				12 Months Ended
	Aug. 31, 2016	Jul. 29, 2016	Dec. 23, 2014	May 17, 2013	Dec. 31, 2016	Dec. 31, 2015	Apr. 17, 2017	Mar. 31, 2017	Aug. 25, 2016	Aug. 09, 2013
Line of Credit Facility [Line Items]
Net Income Loss					$ (7,414,099)	$ (7,898,013)
Accumulated deficit					(136,402,424)	(128,988,325)
Cash					$ 2,657,214	$ 4,706,018
Subsequent Event [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.10438
Working Capital Deficit								$ 5,500,000
Cash								791,000
Accounts Payable and Accrued Liabilities								1,100,000
Subordinated Convertible Promissory Notes [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount							$ 1,000,000
Horizon Technology Finance Corporation [Member] | Subsequent Event [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount								$ 3,600,000
Lender Warrant 2016 [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.0994
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					5,169,577
Class Of Warrant Or Rights Warrant Term					10 years
Venture Loan [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,492,523
Debt Instrument, Payment Terms			The loan was to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan would have been due and payable.
Proceeds from Issuance of Long-term Debt			$ 5,000,000
Warrants Expire Term			10 years
Debt Restructuring 2016 [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					11.27%	11.27%			11.00%
Debt Principal Amount Reduced Percentage					33.00%				33.00%	33.00%
Payments for Other Fees	$ 25,000
Legal Fees	$ 5,000
Debt Instrument, Increase (Decrease) for Period, Description	the final payment was increased from 4.5% of the loan, or $225,000, to 6.5% of the loan, or $325,000
December 2014 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 5,025,000
2013 Warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				50,099,700
Private Placement [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.1003
2014 warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			50,099,700
Warrants [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Price Per Share		$ 0.0994
Sale of Stock, Consideration Received on Transaction		$ 56,262,571
Common Stock [Member]
Line of Credit Facility [Line Items]
Net Income Loss					$ 0
Common Stock [Member] | Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Consideration Received on Transaction		$ 5,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0994
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		56,262,571
Common Stock [Member] | May 2013 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Price Per Share				$ 0.1003
Sale of Stock, Consideration Received on Transaction				$ 12,000,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Line Items]
Raw materials	$ 68,447	$ 112,372
Finished goods	4,617	12,211
Total inventory, net	$ 73,064	$ 124,583

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	181,096,546	109,958,855
Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	31,363,319	21,657,776
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	149,733,227	88,301,079

Summary of Significant Accoun35

Summary of Significant Accounting Policies- Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,500,000	$ 3,200,000
Sales commissions	$ 225,000	302,000
Percentage of cash discount offered to customers	2.00%
Deferred tax assets, valuation allowance	$ 36,388,000	33,455,000
Impairment of Intangible Assets, Finite-lived		66,000
ABG [Member]
Significant Accounting Policies [Line Items]
Purchase Order Placed	3,300,000
Genetic Test Revenue [Member]
Significant Accounting Policies [Line Items]
Breakage Revenue	191,000	$ 218,000
Customer Payment [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	150,000
Kits Components [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	2,400,000
Distributors [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,300,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Prior Period Notice		60 days
Business Combination, Consideration Transferred	$ 250,000
Amway Global [Member]
Business Acquisition [Line Items]
Commissions paid		$ 225,000	$ 302,000
Amway Global [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		24.00%	45.00%
Access Business Group International Llc [Member]
Business Acquisition [Line Items]
Proceeds from License Fees Received		$ 199,000	$ 191,000
ABG [Member]
Business Acquisition [Line Items]
Purchase Order Placed		3,300,000
Payments to Acquire Businesses, Gross		$ 519,000
ABG [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		4.00%	13.00%
ABG [Member] | 2014 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received				$ 1,800,000
ABG [Member] | 2013 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received					$ 1,500,000

Debt Instruments - Additional I

Debt Instruments - Additional Information (Detail) - USD ($)	1 Months Ended			12 Months Ended
	Aug. 31, 2016	Aug. 25, 2016	Dec. 23, 2014	Dec. 31, 2016	Dec. 31, 2015	Aug. 09, 2013
Debt Instrument [Line Items]
Interest Paid				$ 429,267	$ 467,500
Lender Warrant 2016 [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,169,577
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.0994
Intrinsic Value Of Warrants		$ 504,000
Class Of Warrant Or Rights Warrant Term				10 years
Venture Loan [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Long-term Debt			$ 5,000,000
Debt Instrument, Payment Terms			The loan was to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan would have been due and payable.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,492,523
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.1003
Warrants Expire Term			10 years
Interest Expense, Debt		89,000
Intrinsic Value Of Warrants		$ 261,000
Interest Expense, Other				$ 325,000
Debt Instrument, Unamortized Discount				579,000
Interest Paid				429,000	456,000
Paid-in-Kind Interest				294,000	153,000
Venture Loan [Member] | Lender Warrant 2016 [Member]
Debt Instrument [Line Items]
Interest Paid				$ 429,000	$ 456,000
Debt Restructuring 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis				one month LIBOR Rate exceeds 0.50%
Debt Instrument, Interest Rate, Stated Percentage		11.00%		11.27%	11.27%
Interest Expense, Debt		$ 30,000
Debt Principal Amount Reduced Percentage		33.00%		33.00%		33.00%
Payments for Other Fees	$ 25,000
Legal Fees	$ 5,000
Horizon Technology Finance Corporation [Member] | Venture Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis			The loan bore interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeded 0.50%, the interest rate would have been adjusted by an amount equal to the difference between such rates at the end of that particular month.

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Computer software, computer equipment and office equipment	3 years
Laboratory equipment, Useful Life	5 years
Furniture and fixtures, Useful Life	5 years
Leasehold improvements, Useful Life	5 years
Website development, Useful Life	3 years
Computer software, computer equipment and office equipment	$ 516,511	$ 516,511
Laboratory equipment	1,896,417	1,887,454
Furniture and fixtures	40,349	40,349
Leasehold improvements	309,618	309,618
Website development	374,453	298,553
Property, Plant and Equipment, Gross	3,137,348	3,052,485
Less — Accumulated depreciation and amortization	(2,626,156)	(2,408,585)
Total	$ 511,192	$ 643,900

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Utilities Operating Expense, Depreciation and Amortization	$ 218,000	$ 212,000

Intangible Assets (Schedule of

Intangible Assets (Schedule of Intangible Assets) (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Intangible Assets Disclosure [Line Items]
Patent costs	$ 1,154,523	$ 1,154,523
Less — Accumulated amortization	(1,129,094)	(1,029,497)
Less — Write off related to patents no longer in use	0	(66,147)
Total	$ 25,429	$ 58,879

Intangible Assets (Patent Costs

Intangible Assets (Patent Costs Amortized on Straight-Line Basis) (Detail)	Dec. 31, 2016USD ($)
Expected Amortization Expense [Line Items]
2,017	$ 19,117
2,018	6,312
Finite-Lived Intangible Assets, Net, Total	$ 25,429

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Intangible Assets Disclosure [Line Items]
Patent amortization expense	$ 33,450	$ 136,886
Patent life	10 years

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payroll and vacation	$ 81,928	$ 412,674
Other	156,159	85,014
Total accrued expenses	$ 238,087	$ 497,688

Commitments and Contingencies44

Commitments and Contingencies (Detail)	Dec. 31, 2016USD ($)
2,017	$ 344,129
2,018	347,608
2,019	86,864
Operating Leases, Future Minimum Payments Due	778,601
Office Lease [Member]
2,017	335,279
2,018	345,020
2,019	86,864
Operating Leases, Future Minimum Payments Due	767,163
Copier Lease [Member]
2,017	6,624
2,018	1,104
2,019	0
Operating Leases, Future Minimum Payments Due	7,728
Net Lease [Member]
2,017	341,903
2,018	346,124
2,019	86,864
Operating Leases, Future Minimum Payments Due	774,891
Office Equipment [Member]
2,017	2,226
2,018	1,484
2,019	0
Operating Leases, Future Minimum Payments Due	$ 3,710

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2017	May 19, 2016	Dec. 31, 2016	Dec. 31, 2015	Feb. 26, 2014
Loss Contingencies [Line Items]
Operating Leases, Rent Expense			$ 347,000	$ 352,000
Employee-related Liabilities, Current					$ 166,000
Operating Leases Base rent In Year Two			2.06%
Operating Leases Base Rent In Year Three			2.06%
Salaries, Wages and Officers' Compensation		$ 315,000
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage		30.00%
Lease Expiration Date			Mar. 31, 2017
Mr Toutain [Member]
Loss Contingencies [Line Items]
ShareBased Compensation Arrangement By Share Based Payment Granted Percentage Of Common Stock Shares Diluted		1.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,738,933
Mr Toutain [Member] | Share-based Compensation Award, Tranche One [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Mr Toutain [Member] | Share-based Compensation Award, Tranche Two [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		2.083%
Subsequent Event [Member]
Loss Contingencies [Line Items]
Operating Leases Base rent In Year Two	2.88%

Capital Stock (Authorized, Issu

Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Reserved for issuance	201,895,812
Total common shares issued and outstanding at December 31, 2016	229,381,059
Total common shares outstanding and reserved for issuance at December 31, 2016	431,276,871
Warrants with common stock additional purchase rights associated with December 2014 private placement [Member]
Reserved for issuance	50,189,431
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2021
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors [Member]
Reserved for issuance	100,000
Strike Price | $ / shares	$ 0.25
Expiry	Sep. 8, 2024
Debt Restructuring 2016 [Member]
Reserved for issuance	5,169,577
Strike Price | $ / shares	$ 0.0994
Expiry	Aug. 1, 2026
July 2016 Private Placement [Member]
Reserved for issuance	56,262,571
Strike Price | $ / shares	$ 0.0994
Expiry	Jul. 29, 2023
Shares reserved under outstanding stock options and options available for grant [Member]
Reserved for issuance	52,092,463
Shares reserved for future issuance under the Employee Stock Purchase Plan [Member]
Reserved for issuance	70,122
Warrants to purchase common stock associated with December 2014 venture loan and security agreement [Member]
Reserved for issuance	2,492,523
Strike Price | $ / shares	$ 0.1003
Expiry	Dec. 23, 2024
Outstanding warrants issued in June 2012 [Member]
Reserved for issuance	437,158
Strike Price | $ / shares	$ 0.2745
Expiry	Jun. 29, 2017
Outstanding warrants issued in May 2013, vesting May 2013 [Member]
Reserved for issuance	20,655,737
Strike Price | $ / shares	$ 0.2745
Expiry	May 17, 2020
Outstanding warrants issued in May 2013, vesting August 2013 [Member]
Reserved for issuance	14,426,230
Strike Price | $ / shares	$ 0.2745
Expiry	Aug. 9, 2020

Capital Stock (Black Scholes mo

Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail)	1 Months Ended
	Aug. 01, 2016	Jul. 29, 2016
Stockholders Equity [Line Items]
Risk-free interest rate	1.78%
Expected life	10 years
Expected volatility	138.81%
Dividend Yield	0.00%
Warrant [Member]
Stockholders Equity [Line Items]
Risk-free interest rate		1.52%
Expected life		7 years
Expected volatility		147.03%
Dividend Yield		0.00%

Capital Stock (Principal paymen

Capital Stock (Principal payments due under the terms of the Loan Agreement) (Detail) - Loan Agreement	Dec. 31, 2016USD ($)
2,017	$ 2,304,545
2,018	1,920,455
Long-term Debt	$ 4,225,000

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - USD ($)	1 Months Ended					12 Months Ended
	Aug. 25, 2016	Jul. 29, 2016	Dec. 23, 2014	Sep. 30, 2014	May 17, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 09, 2013
Stockholders Equity [Line Items]
Convertible preferred stock, par value						$ 0.001	$ 0.001
Convertible preferred stock, shares authorized						6,000,000	6,000,000
Common stock, shares authorized						450,000,000	300,000,000
Common stock, par value						$ 0.001	$ 0.001
Common stock, shares outstanding						229,381,059	172,887,221
Allocated Share-based Compensation Expense						$ 9,000	$ 12,000
Common Stock Shares Issued						229,381,059	172,887,221
Debt Conversion, Converted Instrument, Shares Issued						2,521,222
Interest Paid						$ 429,267	$ 467,500
Debt Conversion, Original Debt, Amount						14,316,255
May 2013 Private Placement [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized									150,000,000
May 2013 Private Placement [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized									300,000,000
Venture Loan [Member]
Stockholders Equity [Line Items]
Warrants exercise price per share			$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,492,523
Proceeds from Issuance of Long-term Debt			$ 5,000,000
Interest Paid						429,000	456,000
Paid-in-Kind Interest						294,000	153,000
Debt Instrument, Unamortized Discount						$ 579,000
Debt Restructuring 2016 [Member]
Stockholders Equity [Line Items]
Warrant Expiration Period	10 years
Debt Principal Amount Reduced Percentage	33.00%					33.00%			33.00%
Investor [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction		$ 5,600,000	$ 5,025,000
Sale of Stock, Number of Shares Issued in Transaction		56,262,571	50,099,700
Warrants exercise price per share		$ 0.0994	$ 0.1003
Sale of Stock, Price Per Share		$ 0.0994	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		56,262,571	50,099,700
Warrant Expiration Period		7 years	7 years
Danforth Advisors [Member]
Stockholders Equity [Line Items]
Common stock, par value				$ 0.25
Warrants Fair Value Disclosure						$ 24,000
Common Stock Shares Issued				100,000
Warrant Expiration Period				10 years
Common Stock [Member]
Stockholders Equity [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion						39,089,161
Common Stock [Member] | May 2013 Private Placement [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction					$ 12,000,000
Sale of Stock, Number of Shares Issued in Transaction					43,715,847
Sale of Stock, Price Per Share					$ 0.1003
Warrants 2013 [Member]
Stockholders Equity [Line Items]
Percentage Of Warrants Exercisable					63.00%
Percentage Of Warrants Exercisable After Shareholder Approval					37.00%
Warrants exercise price per share					$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					32,786,885
Warrants 2014 [Member]
Stockholders Equity [Line Items]
Warrants Fair Value Disclosure			$ 261,000
Warrants and Rights Outstanding								$ 5,200,000
Warrant Expiration Period			10 years
Warrants 2016 [Member]
Stockholders Equity [Line Items]
Warrants Fair Value Disclosure						$ 6,500,000
Lender Warrant 2016 [Member]
Stockholders Equity [Line Items]
Warrants exercise price per share						$ 0.0994
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						5,169,577
Warrants and Rights Outstanding						$ 504,000
Lender Warrant 2016 [Member] | Venture Loan [Member]
Stockholders Equity [Line Items]
Interest Paid						429,000	$ 456,000
Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense						$ 780,000
Warrants To Purchase Of Common Stock						2,295,082
Warrants exercise price per share						$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			89,731
Warrants and Rights Outstanding								$ 9,000
Payments for Underwriting Expense			$ 218,000			$ 63,000

Stock-Based Compensation Arra50

Stock-Based Compensation Arrangements (Stock-based compensation expense for stock option awards) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Risk-free interest rate	1.24%	1.54%
Expected life	5 years 8 months 23 days	5 years 8 months 23 days
Expected volatility	146.30%	138.80%
Dividend yield	0.00%	0.00%

Stock-Based Compensation Arra51

Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shares
Outstanding, beginning of period	21,657,776	4,523,900
Granted	10,622,392	18,193,027
Stock options exercised	(1,316)	0
Restricted stock exercised	0	0
Forfeited/Expired	(915,533)	(1,059,151)
Outstanding, end of period	31,363,319	21,657,776
Exercisable, end of period	10,860,050	3,665,124
Weighted Avg. Exercise Price
Outstanding, beginning of period	$ 0.21	$ 0.39
Granted	0.16	0.17
Stock options exercised	0.05	0
Restricted stock exercised	0	0
Forfeited/Expired	0.33	0.17
Outstanding, end of period	0.19	0.21
Exercisable, end of period	$ 0.23	$ 0.32

Stock-Based Compensation Arra52

Stock-Based Compensation Arrangements (Stock options and restricted stock outstanding and exercisable) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	31,363,319	21,657,776	4,523,900
Outstanding, Weighted Avg. Exercise Price	$ 0.19	$ 0.21	$ 0.39
Exercisable, Shares	10,860,050	3,665,124
Exercisable, Weighted Avg. Exercise Price	$ 0.23	$ 0.32
Stock Option Or Restricted Stock Outstanding [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	31,363,319
Outstanding, Weighted Avg. remaining contractual life	8 years 6 months 14 days
Outstanding, Weighted Avg. Exercise Price	$ 0.19
Aggregate intrinsic value	$ 69,547
Stock Option Or Restricted Stock Outstanding [Member] | $0.01-$1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	31,318,319
Outstanding, Weighted Avg. remaining contractual life	8 years 6 months 18 days
Outstanding, Weighted Avg. Exercise Price	$ 0.19
Stock Option Or Restricted Stock Outstanding [Member] | $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	45,000
Outstanding, Weighted Avg. remaining contractual life	1 year 3 months
Outstanding, Weighted Avg. Exercise Price	$ 1.40
Stock Option Or Restricted Stock Outstanding [Member] | $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Outstanding [Member] | $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Outstanding [Member] | $4.01-$5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	10,860,050
Exercisable, Weighted Avg. Exercise Price	$ 0.23
Aggregate intrinsic value	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $0.01-$1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	10,815,050
Exercisable, Weighted Avg. Exercise Price	$ 0.23
Stock Option Or Restricted Stock Exercisable [Member] | $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	45,000
Exercisable, Weighted Avg. Exercise Price	$ 1.40
Stock Option Or Restricted Stock Exercisable [Member] | $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $4.01-$5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0

Stock-Based Compensation Arra53

Stock-Based Compensation Arrangements (Non-vested options) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Non-vested options, beginning of year	17,992,652	2,878,739
Non-vested options, beginning of year, Weighted Avg Exercise Price	$ 0.18	$ 0.37
Granted, Shares	10,622,392	18,193,027
Granted, Weighted Avg Exercise Price	$ 0.16	$ 0.17
Vested, Shares	(8,035,609)	(2,038,435)
Vested, Weighted Avg Exercise Price	$ 0.15	$ 0.33
Forfeited, Shares	(76,166)	(1,040,679)
Forfeited, Weighted Avg Exercise Price	$ 0.25	$ 0.17
Non-vested options, end of year, Shares	20,503,269	17,992,652
Non-vested options, end of year, Weighted Avg Exercise Price	$ 0.17	$ 0.18

Stock-Based Compensation Arra54

Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation	$ 971,688	$ 892,087
Stock option grants beginning of period [Member]
Share-based Compensation	846,347	730,102
Stock option grants [Member]
Share-based Compensation	122,420	157,932
Employee Stock Purchase Plan [Member]
Share-based Compensation	2,921	4,053
Director agreements [Member]
Share-based Compensation	$ 0	$ 0

Stock-Based Compensation Arra55

Stock-Based Compensation Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 20, 2016	Jul. 21, 2015	Dec. 31, 2016	Dec. 31, 2015	Aug. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value			$ 0.15	$ 0.16
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options			$ 2,705,027	$ 2,248,591
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value			$ 0.11
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 9 months 18 days	3 years 1 month 10 days
Granted,Weighted Avg.Exercise Price			$ 0.16	$ 0.17
Employment Agreement Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,000,000
Granted,Weighted Avg.Exercise Price	$ 0.17544
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	These options will vest as to 25% of the shares on July 29, 2017 and as to an additional 2.083% of the shares on the last day of each successive month thereafter
Share based Compensation Arrangements By Share based Payment Award Options Grants In Period Percentage			5.00%
Conversion of Stock, Shares Converted	5,626,257
Employment Agreement One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,738,933
Granted,Weighted Avg.Exercise Price	$ 0.17544
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	These options will vest as to 25% of the shares on August 15, 2017, and as to an additional 2.083% of the shares monthly thereafter.
Share based Compensation Arrangements By Share based Payment Award Options Grants In Period Percentage			1.00%
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			229,951
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price			85.00%
Weighted-average purchase price			$ 0.08	0.10
Weighted-average fair value			$ 0.09	$ 0.12
Compensation expense			$ 2,921	$ 4,053
Employee Stock Purchase Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			229,951	203,879
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized			5,000,000		8,860,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		30,000,000	10,622,392
2013 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			20,729,144
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized					2,435,500

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	25.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 1,500
Defined Contribution Plan, Cost Recognized	$ 13,520	$ 2,239

Income Taxes (Deferred tax asse

Income Taxes (Deferred tax assets (liabilities) (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax asset:
Net operating loss carryforwards	$ 31,398,000	$ 29,122,000
Accrued expenses	19,000	87,000
Amortization of definite lived intangible assets	0	10,000
Non-qualified stock option compensation	598,000	315,000
Depreciation	68,000	72,000
Deferred revenue	943,000	880,000
Other	1,000	139,000
Patents	0	(23,000)
Deferred gain on installment sale	(1,000)	0
State net operating loss carryforwards, net of federal tax benefit	929,000	579,000
Research tax credit carryforwards	2,433,000	2,274,000
Total deferred tax assets	36,388,000	33,455,000
Valuation allowance	(36,388,000)	(33,455,000)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Provision for inc

Income Taxes (Provision for income taxes) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Tax at statutory rate	(34.00%)	(34.00%)
State taxes, net of federal benefit	0.00%	0.00%
Research and development credit	(0.69%)	(1.30%)
Share based payment expense	0.00%	1.60%
Other	0.42%	0.70%
Removal of deferred tax asset on federal net operating losses	0.00%	0.00%
Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits	(5.30%)	(4.90%)
Change in valuation allowance	39.60%	37.90%
Effective tax rate	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 94.9
Equity Method Investment, Ownership Percentage	50.00%
Additional Paid-In Capital [Member]
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 94.9
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	2.5
Research Tax Credit Carryforward [Member]
Income Taxes Disclosure [Line Items]
Tax Credit Carryforward, Amount	1.7
State and Local Jurisdiction [Member]
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 17.6
Operating Loss Carryforward Of Expiration Year	2,036
Tax Credit Carryforward, Amount	$ 1.1

Risks and Uncertainties - Addit

Risks and Uncertainties - Additional Information (Detail) - Sales Revenue, Net [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Merchant Network And Channel Partner [Member]
Concentration Risk [Line Items]
Sales Revenue Goods Net Percentage	24.00%	45.00%
ABG’s promotional product [Member]
Concentration Risk [Line Items]
Sales Revenue Goods Net Percentage	4.00%	13.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 17, 2017	Jan. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Granted,Weighted Avg.Exercise Price			$ 0.16	$ 0.17
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.10438
Class of Warrant or Right, Expiration Term	10 years
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	11,039,209
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,519,604
Subsequent Event [Member] | Subordinated Convertible Promissory Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 1,000,000
Subsequent Event [Member] | Subordinated Convertible Promissory Notes [Member] | Bay City Capital [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	500,000
Subsequent Event [Member] | Subordinated Convertible Promissory Notes [Member] | Horizon Technology Finance Corporation [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 500,000
Subsequent Event [Member] | Employment Agreement One [Member]
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		1,278,653
Granted,Weighted Avg.Exercise Price		$ 0.1237
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The option vests as to ¼ of the shares on January 25, 2018, and as to 1/36 of the remaining unvested shares at the beginning of each calendar month thereafter beginning on February 1, 2018
Subsequent Event [Member] | Employment Agreement Two [Member]
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		3,625,746
Granted,Weighted Avg.Exercise Price		$ 0.1237
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The option vests as to ¼ of the shares on January 25, 2018, and as to 1/36 of the remaining unvested shares at the beginning of each calendar month thereafter beginning on February 1, 2018
Subsequent Event [Member] | Employment Agreement Three [Member]
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		365,093
Granted,Weighted Avg.Exercise Price		$ 0.1237
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The option vests as to ¼ of the shares on January 25, 2018, and as to 1/36 of the remaining unvested shares at the beginning of each calendar month thereafter beginning on February 1, 2018.